To determine if candesartan, compared with placebo, reduces the combined endpoint of
• cardiovascular mortality, hospitalization for the management of CHF, or nonfatal myocardial infarction
• cardiovascular mortality, or hospitalization for the management of CHF or nonfatal myocardial infarction, or coronary revascularization
procedures
• all-cause mortality and all-cause hospitalization
The influence of assignment to candesartan on each of the individual components of the above composite endpoints will be evaluated.
The effects of candesartan on functional state and symptoms according to NYHA classification, as well as the safety and tolerability, will be
determined.
The influences with use of candesartan on health care costs will be determined.
To determine if candesartan, compared with placebo, reduces the combined endpoint of• cardiovascular mortality, hospitalization for the management of CHF, or nonfatal myocardial infarction• cardiovascular mortality, or hospitalization for the management of CHF or nonfatal myocardial infarction, or coronary revascularizationprocedures• all-cause mortality and all-cause hospitalizationThe influence of assignment to candesartan on each of the individual components of the above composite endpoints will be evaluated.The effects of candesartan on functional state and symptoms according to NYHA classification, as well as the safety and tolerability, will bedetermined.The influences with use of candesartan on health care costs will be determined.
การแปล กรุณารอสักครู่..
